The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BGLC | +43.37% | -82.4% | -29.35% | -91% |
| S&P | +13.22% | +85.17% | +13.11% | +102% |
BioNexus Gene Lab Corp. is a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.
No news articles found for BioNexus Gene Lab.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.54M | -3.3% |
| Gross Profit | $0.38M | 29.2% |
| Gross Margin | 14.85% | 3.7% |
| Market Cap | $9.83M | 1374.9% |
| Market Cap / Employee | $0.33M | 0.0% |
| Employees | 30 | 66.7% |
| Net Income | -$0.71M | 47.3% |
| EBITDA | -$0.77M | 56.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.89M | -30.0% |
| Accounts Receivable | $1.52M | 6.8% |
| Inventory | 1 | -27.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.13M | -28.8% |
| Short Term Debt | $0.06M | 17.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -24.68% | -16.3% |
| Return On Invested Capital | -4.89% | 0.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.24M | 23.6% |
| Operating Free Cash Flow | -$1.23M | 13.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.05 | 0.05 | 0.71 | 1.31 | 1740.14% |
| Price to Sales | 0.53 | 0.46 | 0.58 | 1.04 | 20.25% |
| Price to Tangible Book Value | 0.45 | 0.38 | 0.71 | 1.31 | 90.34% |
| Enterprise Value to EBITDA | 1.34 | -1.48 | -4.03 | -9.28 | 298.45% |
| Return on Equity | -17.8% | -24.7% | -34.4% | -28.3% | 187.16% |
| Total Debt | $0.21M | $0.20M | $0.20M | $0.18M | -18.90% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
